Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Tang, Yuting ^a   Ho, George ^a   Li, Yaxin ^a   Hall, Meghan A ^a   Hills, Robert L ^a   Black, Shawn C ^a   Liang, Yin ^a   Demarest, Keith T ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTISENSE OLIGONUCLEOTIDE; CANNABINOID 1 RECEPTOR; CARRIER PROTEIN; CD36 ANTIGEN; FATTY ACID; GLUCOSE; LEPTIN; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; EPIDIDYMIS FAT; FATTY LIVER; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; KIDNEY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE, WHITE; ANIMALS; ANTIGENS, CD36; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; FEMALE; GLUCOSE; INSULIN; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED AKR; OBESITY; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; ORGAN SPECIFICITY; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

MUS;

EID: 84864533340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042134     Document Type: Article

References (68)

1. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F, ((2010)) The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95: 375-382.
2. Scheen AJ, ((2009)) The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 10: 56-74.
3. Vemuri VK, Janero DR, Makriyannis A, ((2008)) Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome. Physiol Behav 93: 671-686.
4. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, et al. ((2008)) The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 74: 1678-1686.
5. Baldassano S, Serio R, Mule F, ((2008)) Cannabinoid CB1 receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur J Pharmacol 582: 132-138.
6. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, et al. ((2005)) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305.
7. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, et al. ((2000)) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835-840.
8. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, et al. ((2008)) Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51: 476-487.
9. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, et al. ((2007)) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92: 4810-4819.
10. Janero DR, Makriyannis A, ((2009)) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerging Drugs 14: 43-65.
11. Despres J-P, ((2009)) Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 15: 553-570.
12. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S, ((2008)) Endocannabinoids and the Control of Energy Homeostasis. J Biol Chem 283: 33021-33025.
13. Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, et al. ((2005)) Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81: 273-282.
14. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. ((2001)) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
15. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. ((2006)) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180.
16. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, et al. ((2008)) Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet. Obesity 16: 553-565.
17. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, et al. ((2006)) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053-3060.
18. Engeli S, Boehnke J, Feldpausch M, Gorzelniak K, Janke J, et al. ((2005)) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843.
19. Jumpertz R, Guijarro A, Pratley RE, Piomelli D, Krakoff J, ((2011)) Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J Clin Endocrinol Metab 96: 787-791.
20. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, et al. ((2004)) Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24: 2708-2715.
21. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, et al. ((1998)) In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125: 1393-1395.
22. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, et al. ((2002)) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 9612-9617.
23. Cota D, Marsicano G, Tschoep M, Gruebler Y, Flachskamm C, et al. ((2003)) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431.
24. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, et al. ((2003)) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908-914.
25. Getty-Kaushik L, Richard AM, Deeney JT, Krawczyk S, Shirihai O, et al. ((2009)) The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring) 17: 1856-1860.
26. Bermudez-Silva FJ, Suarez Perez J, Nadal A, Rodriguez de Fonseca F, ((2009)) The role of the pancreatic endocannabinoid system in glucose metabolism. Best Pract Res, Clin Endocrinol Metab 23: 87-102.
27. Jiang L-s, Pu J, Han Z-h, Hu L-h, He B, ((2009)) Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 81: 805-813.
28. Crespillo A, Suarez J, Bermudez-Silva FJ, Rivera P, Vida M, et al. ((2011)) Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J 433: 175-185.
29. Corbille A-G, Valjent E, Marsicano G, Ledent C, Lutz B, et al. ((2007)) Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 27: 6937-6947.
30. Svizenska I, Dubovy P, Sulcova A, ((2008)) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures- a short review. Pharmacol, Biochem Behav 90: 501-511.
31. Silvestri C, Ligresti A, Di Marzo V, ((2011)) Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 12: 153-162.
32. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, et al. ((1999)) Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis 143: 81-90.
33. Lobo SM, Quinto BM, Oyama L, Nakamichi R, Ribeiro AB, et al. ((2012)) TNF-alpha modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. Cytokine. (in press).
34. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, et al. ((2010)) CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 59: 926-934.
35. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, et al. ((2003)) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-353.
36. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, et al. ((2005)) The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19: 1567-1569.
37. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, et al. ((2008)) Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 57: 2028-2036.
38. Migrenne S, Lacombe A, Lefevre A-L, Pruniaux M-P, Guillot E, et al. ((2009)) Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am J Physiol 296: R929-R935.
39. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, et al. ((2007)) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129.
40. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, et al. ((2009)) Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 284: 1803-1812.
41. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, et al. ((2005)) Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90: 1434-1439.
42. Despres JP, Golay A, Sjostrom L, ((2005)) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134.
43. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, et al. ((2010)) Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 285: 33623-33631.
44. Chang LC, Huang KC, Wu YW, Kao HL, Chen CL, et al. ((2009)) The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 108: 353-366.
45. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P, ((2004)) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28: 640-648.
46. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, et al. ((1997)) Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 99: 385-390.
47. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, et al. ((2002)) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339-343.
48. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, et al. ((2010)) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120: 2953-2966.
49. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, et al. ((1996)) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118: 2023-2028.
50. Buettner C, Muse ED, Cheng A, Chen L, Scherer T, et al. ((2008)) Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14: 667-675.
51. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, et al. ((2010)) CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 11: 273-285.
52. Verty ANA, Allen AM, Oldfield BJ, ((2009)) The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure. Obesity FIELD Full Journal Title:Obesity 17: 254-261.
53. Xu X, Liu Y, Huang S, Liu G, Xie C, et al. ((2006)) Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171: 31-38.
54. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, et al. ((2006)) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676.
55. Moezi L, Gaskari SA, Liu H, Baik SK, Dehpour AR, et al. ((2006)) Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 149: 898-908.
56. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, et al. ((2008)) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118: 3160-3169.
57. Friedman SL, Nieto N, ((2008)) Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors. Cell Metab 7: 187-188.
58. Evans RM, Barish GD, Wang YX, ((2004)) PPARs and the complex journey to obesity. Nat Med 10: 355-361.
59. Wang Q, Perrard XD, Perrard JL, Mansoori A, Smith CW, et al. ((2011)) Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity (Silver Spring) 19: 505-513.
60. Liu YL, Connoley IP, Wilson CA, Stock MJ, ((2005)) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice. Int J Obes 29: 183-187.
61. Nakata M, Yada T, ((2008)) Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept 145: 49-53.
62. Marsenic O, ((2009)) Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 53: 875-883.
63. Stumvoll M, Meyer C, Perriello G, Kreider M, Welle S, et al. ((1998)) Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol 274: E817-826.
64. Agudo J, Martin M, Roca C, Molas M, Bura AS, et al. ((2010)) Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 53: 2629-2640.
65. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, Serrano A, Fuentes E, et al. ((2007)) Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 565: 207-211.
66. De Gottardi A, Spahr L, Ravier-Dall'Antonia F, Hadengue A, ((2010)) Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. Liver Int 30: 1482-1489.
67. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, et al. ((2009)) Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 4: e5844.
68. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, et al. ((2007)) Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 27: 215-219.